ATE287900T1 - Das antigen ha-1 - Google Patents

Das antigen ha-1

Info

Publication number
ATE287900T1
ATE287900T1 AT98936758T AT98936758T ATE287900T1 AT E287900 T1 ATE287900 T1 AT E287900T1 AT 98936758 T AT98936758 T AT 98936758T AT 98936758 T AT98936758 T AT 98936758T AT E287900 T1 ATE287900 T1 AT E287900T1
Authority
AT
Austria
Prior art keywords
cells
tumor cells
hematopoietic
derivatives
peptide
Prior art date
Application number
AT98936758T
Other languages
English (en)
Inventor
Elsa Afra Julia Maria Goulmy
Donald Frederick Hunt
Victor Henry Engelhard
Original Assignee
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE287900T1 publication Critical patent/ATE287900T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98936758T 1997-07-23 1998-07-23 Das antigen ha-1 ATE287900T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202303 1997-07-23
PCT/NL1998/000424 WO1999005173A1 (en) 1997-07-23 1998-07-23 The ha-1 antigen

Publications (1)

Publication Number Publication Date
ATE287900T1 true ATE287900T1 (de) 2005-02-15

Family

ID=8228585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936758T ATE287900T1 (de) 1997-07-23 1998-07-23 Das antigen ha-1

Country Status (11)

Country Link
US (3) US6878375B1 (de)
EP (1) EP0996636B1 (de)
JP (1) JP2001510851A (de)
AT (1) ATE287900T1 (de)
AU (2) AU756962B2 (de)
CA (1) CA2298887A1 (de)
DE (1) DE69828791T2 (de)
DK (1) DK0996636T3 (de)
ES (1) ES2236924T3 (de)
PT (1) PT996636E (de)
WO (2) WO1999005173A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756962B2 (en) * 1997-07-23 2003-01-30 Rijksuniversiteit Te Leiden The HA-1 antigen
US20040092446A1 (en) * 1997-07-23 2004-05-13 Goulmy Elsa A.J.M. HA-1 epitopes and uses thereof
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
EP1317927A1 (de) * 2001-12-05 2003-06-11 Academisch Ziekenhuis Leiden Nebenhistokompatibilitätsantigen HA-1: Zielantigen für Immuntherapie von Tumoren
EP3256488A4 (de) * 2015-02-09 2018-10-17 Université de Montréal Neuartige neben-histokompatibilitäts-antigenen und verwendungen davon
CN109996868A (zh) * 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
CN110121359A (zh) * 2016-11-11 2019-08-13 怀特黑德生物制剂研究所 人血浆培养基
EP3585800A4 (de) * 2017-02-22 2021-06-02 The Universite de Montreal Neuartige neben-histokompatibilitäts-antigenen und verwendungen davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
ES2259181T3 (es) * 1995-07-25 2006-09-16 Rijksuniversiteit Te Leiden Peptido antigenico ha-2.
NZ313774A (en) 1995-07-27 1999-11-29 Univ Leiden The h-y antigen
AU6602896A (en) 1995-07-28 1997-02-26 University Of Virginia Patent Foundation H-y derived epitopes and uses therefor
EP0965648A1 (de) 1998-06-02 1999-12-22 Rijksuniversiteit Leiden Verfahren zur Genomtypisierung des Nebenhistokompatibilitätsantigens (minor histocompatibility antigen) HA-1
AU756962B2 (en) 1997-07-23 2003-01-30 Rijksuniversiteit Te Leiden The HA-1 antigen
US6830883B1 (en) 1997-07-23 2004-12-14 Rijksuniversiteit Leiden Method for typing of minor histocompatibility antigen HA-1
EP1170589A1 (de) 2000-06-05 2002-01-09 Stichting Sanquin Bloedvoorziening Verfahren zur Histokompatibilitätsuntersuchung
EP1317927A1 (de) 2001-12-05 2003-06-11 Academisch Ziekenhuis Leiden Nebenhistokompatibilitätsantigen HA-1: Zielantigen für Immuntherapie von Tumoren

Also Published As

Publication number Publication date
US7205119B2 (en) 2007-04-17
DK0996636T3 (da) 2005-04-25
EP0996636A1 (de) 2000-05-03
AU8564098A (en) 1999-02-16
AU8563998A (en) 1999-02-16
WO1999005174A1 (en) 1999-02-04
US6878375B1 (en) 2005-04-12
ES2236924T3 (es) 2005-07-16
US20040191268A1 (en) 2004-09-30
DE69828791T2 (de) 2006-01-12
DE69828791D1 (de) 2005-03-03
US20080206268A1 (en) 2008-08-28
EP0996636B1 (de) 2005-01-26
CA2298887A1 (en) 1999-02-04
PT996636E (pt) 2005-05-31
AU756962B2 (en) 2003-01-30
WO1999005173A1 (en) 1999-02-04
JP2001510851A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
Yoshino et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
Lu et al. Cancer immunotherapy targeting neoantigens
EP2359841A3 (de) Von Survivin abgeleitete Peptide und deren Verwendung
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
PT1734049E (pt) Peptídeos associados a tumores de ligação à molécula mhc
Sommerfeldt et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients
Kobayashi et al. Defining MHC class II T helper epitopes for WT1 tumor antigen
Tamir et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors
AU2003267401A1 (en) Novel mhc ii associated peptides
DE69828791D1 (de) Das antigen ha-1
Hueman et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
Kobayashi et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP
WO2020127546A3 (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
von Bergwelt-Baildon et al. Correspondence re R. Lapointe et al., CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells. Cancer Res 2003; 63: 2836–43.
BR0012446A (pt) Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma
Slingluff Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms
ATE318842T1 (de) Antigenische ha-2 peptide
Parmiani et al. Tumor immunology: molecularly defined antigens and clinical applications
CO5300468A1 (es) Antigeno asociado con tumores
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
Packard et al. Tumor cell recognition by lymphocytes: is the MHC always essential?
Cerundolo Use of major histocompatibility complex class I tetramers to monitor tumor-specific cytotoxic T lymphocyte response in melanoma patients
Ouyang et al. Induced Pluripotent Stem Cell-Based
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0996636

Country of ref document: EP

REN Ceased due to non-payment of the annual fee